Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C. et al.
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

Ann Oncol 2015;
26: 1877-83

Bibliographische Angaben herunterladen

Aufrufen in: